Scorpion Therapeutics is carving a niche in the field of precision oncology since its founding in 2020. It aims to redefine cancer treatment paradigms through its slogan, "Pioneering the Next Generation of Precision Oncology". This Biotechnology and Life Sciences company is characterized by its robust pipeline, spearheaded by the mutant-selective PI3Ka program, STX-478. With three clinical product candidates and multiple discovery-stage programs, Scorpion addresses critical gaps with targeted therapies for previously undruggable cancer targets.
Following its $150.00M Series C investment on 16 July 2024, the company has attracted attention from a consortium of prestigious investors including Lightspeed Venture Partners, Atlas Venture, Casdin Capital, and others. These investors highlight confidence in Scorpion's proprietary platform that integrates cancer biology, medicinal chemistry, and data sciences, setting promising prospects for improved patient outcomes in the global oncology landscape.
